260 related articles for article (PubMed ID: 12425369)
21. A randomized controlled trial comparing transurethral resection of the prostate, contact laser prostatectomy and electrovaporization in men with benign prostatic hyperplasia: analysis of subjective changes, morbidity and mortality.
van Melick HH; van Venrooij GE; Eckhardt MD; Boon TA
J Urol; 2003 Apr; 169(4):1411-6. PubMed ID: 12629374
[TBL] [Abstract][Full Text] [Related]
22. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
23. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
Gallegos PJ; Frazee LA
Pharmacotherapy; 2008 Mar; 28(3):356-65. PubMed ID: 18294115
[TBL] [Abstract][Full Text] [Related]
24. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
[TBL] [Abstract][Full Text] [Related]
25. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
[TBL] [Abstract][Full Text] [Related]
26. [Benign hypertrophy of the prostate].
Descazeaud A; de La Taille A
Rev Prat; 2006 Dec; 56(20):2283-9. PubMed ID: 17352329
[No Abstract] [Full Text] [Related]
27. Urodynamics after TURP and HoLEP in urodynamically obstructed patients: are there any differences at 1 year of follow-up?
Rigatti L; Naspro R; Salonia A; Centemero A; Ghezzi M; Guazzoni G; Briganti A; Rigatti P; Montorsi F
Urology; 2006 Jun; 67(6):1193-8. PubMed ID: 16750253
[TBL] [Abstract][Full Text] [Related]
28. The resolution of detrusor over activity after medical and surgical treatment in patients with bladder outlet obstruction.
Sriplakich S; Promwatcharanon K
J Med Assoc Thai; 2007 Nov; 90(11):2326-31. PubMed ID: 18181315
[TBL] [Abstract][Full Text] [Related]
29. [Symptoms of the lower urinary tract suggesting infravesical obstruction].
Monteiro H
Acta Med Port; 1999; 12(1-3):23-6. PubMed ID: 10423869
[TBL] [Abstract][Full Text] [Related]
30. Prostatic stents and balloon dilatation.
McLoughlin J; Williams G
Br J Hosp Med; 1990 Jun; 43(6):422-6. PubMed ID: 1694704
[TBL] [Abstract][Full Text] [Related]
31. [Differential diagnosis and therapy examined under the microscope. LUTS (lower urinary tract symptoms) due to OAB (overactive bladder) - a frequent disease picture in the man].
MMW Fortschr Med; 2011 Mar; 153(13):44-5. PubMed ID: 21638816
[No Abstract] [Full Text] [Related]
32. 5alpha-reductase inhibition for men with enlarged prostate.
Issa MM; Kraft KH
J Am Acad Nurse Pract; 2007 Aug; 19(8):398-407. PubMed ID: 17655569
[TBL] [Abstract][Full Text] [Related]
33. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder.
Chapple CR; Roehrborn CG
Eur Urol; 2006 Apr; 49(4):651-8. PubMed ID: 16530611
[TBL] [Abstract][Full Text] [Related]
34. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
35. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?
Barendrecht MM; Abrams P; Schumacher H; de la Rosette JJ; Michel MC
Neurourol Urodyn; 2008; 27(3):226-30. PubMed ID: 17638312
[TBL] [Abstract][Full Text] [Related]
36. Enlarging the scope of managing benign prostatic hyperplasia: addressing sexual function and quality of life.
Martin DJ; Mulhall JP
Int J Clin Pract; 2005 May; 59(5):579-90. PubMed ID: 15857355
[TBL] [Abstract][Full Text] [Related]
37. Management of benign prostatic hyperplasia by the primary care physician in the 21st century: the new paradigm.
Barkin J
Can J Urol; 2008 Aug; 15 Suppl 1():21-30; discussion 30. PubMed ID: 18700062
[TBL] [Abstract][Full Text] [Related]
38. The effects of treating lower urinary tract symptoms on health-related quality of life: a short-term outcome.
Quek KF; Loh CS; Low WY; Razack AH; Chua CB
Singapore Med J; 2002 Aug; 43(8):391-8. PubMed ID: 12507023
[TBL] [Abstract][Full Text] [Related]
39. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
DiSantostefano RL; Biddle AK; Lavelle JP
BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339
[TBL] [Abstract][Full Text] [Related]
40. Urodynamic evaluation in diabetic patients with prostate enlargement and lower urinary tract symptoms.
Dib PT; Trigo-Rocha F; Gomes CM; Srougi M
Urol Int; 2008; 80(4):378-82. PubMed ID: 18587248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
